ArticleThe American journal of pathology2010
Characterization of a mouse model of hyperglycemia and retinal neovascularization.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 113 citations in OpenAlex.
- Loss of mitochondrial DNA helicase in retinal macroglia drives neovascular retinopathy.EMBO molecular medicine · 2026Article
- Models of hyperglycaemia in diabetes mellitus and its complications.Nature reviews. Endocrinology · 2026Review
- Single-cell insights into maladaptive endothelial plasticity and therapeutic targets in diabetic vascular complications.Cardiovascular diabetology · 2026Review
- In search of a mouse model of Spaceflight Associated Neuro-ocular Syndrome using one-carbon genetics.Scientific reports · 2026Article
- Small Extracellular Vesicles Released from ARPE-19 Cells Grown under Diabetic Retinopathy Conditions Promote NLRP3 Inflammasome Activation.ACS biomaterials science & engineering · 2025Article
- Diabetic Retinopathy, a Comprehensive Overview on Pathophysiology and Relevant Experimental Models.International journal of molecular sciences · 2025Review
- NLRP3 inflammasomes pathway: a key target for Metformin.Inflammopharmacology · 2025Review
- Single-cell sequencing in diabetic retinopathy: progress and prospects.Journal of translational medicine · 2025Review
- Characterization of RNA editing and gene therapy with a compact CRISPR-Cas13 in the retina.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Heterotypic macrophages/microglia differentially contribute to retinal ischaemia and neovascularisation.Diabetologia · 2024Article
- Impairment of flicker-induced increase in retinal blood flow in diabetic pigs.Japanese journal of ophthalmology · 2024Article
- Beneficial Effect of Sirolimus-Pretreated Mesenchymal Stem Cell Implantation on Diabetic Retinopathy in Rats.Biomedicines · 2024Article
- Imaging Histology Correlations of Intraretinal Fluid in Neovascular Age-Related Macular Degeneration.Translational vision science & technology · 2023Article
- Diabetic retinopathy: a comprehensive update on in vivo, in vitro and ex vivo experimental models.BMC ophthalmology · 2023Review
- Review
- The Warburg effect alters amino acid homeostasis in human retinal endothelial cells: implication for proliferative diabetic retinopathy.Scientific reports · 2023Article
- SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes.iScience · 2023Article
- Akimba Proliferative Diabetic Retinopathy Model: Understanding Molecular Mechanism and Drug Screening for the Progression of Diabetic Retinopathy.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Mouse microphthalmia-associated transcription factor (Mitf) mutations affect the structure of the retinal vasculature.Acta ophthalmologica · 2022Article
- Diabetic macular ischaemia- a new therapeutic target?Progress in retinal and eye research · 2022Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of the limitations of research into diabetic retinopathy is the lack of suitable animal models. To study how the two important factors--hyperglycemia and vascular endothelial growth factor--interact in diabetic retinopathy, the Akimba mouse (Ins2AkitaVEGF+/-) was generated by crossing the Akita mouse (Ins2Akita) with the Kimba mouse (VEGF+/+). C57Bl/6 and the parental and Akimba mouse lines were characterized by biometric measurements, histology, immunohistochemistry, and Spectralis Heidelberg retinal angiography and optical coherence tomography. The Akimba line not only retained the characteristics of the parental strains, such as developing hyperglycemia and retinal neovascularization, but developed higher blood glucose levels at a younger age and had worse kidney-body weight ratios than the Akita line. With aging, the Akimba line demonstrated enhanced photoreceptor cell loss, thinning of the retina, and more severe retinal vascular pathology, including more severe capillary nonperfusion, vessel constriction, beading, neovascularization, fibroses, and edema, compared with the Kimba line. The vascular changes were associated with major histocompatibility complex class II+ cellular staining throughout the retina. Together, these observations suggest that hyperglycemia resulted in higher prevalences of edema and exacerbated the vascular endothelial growth factor-driven neovascular and retinal changes in the Akimba line. Thus, the Akimba line could become a useful model for studying the interplay between hyperglycemia and vascular endothelial growth factor and for testing treatment strategies for potentially blinding complications, such as edema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.